Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve significant growth in 2025, driven by a combination of "deep cultivation, overseas expansion, and licensing" strategies [5] - In 2025, the company is projected to generate revenue of 3.387 billion yuan (up 13.56% year-on-year) and a net profit attributable to shareholders of 372 million yuan (up 19.20%) [5] - The company has seen a strong increase in Q4 2025, with revenue reaching 990 million yuan (up 34.79%) and net profit of 111 million yuan (up 86.17%) [5] - The company maintains a steady improvement in profitability, with a gross margin of 53.16% (up 1.31 percentage points) and a net margin of 10.93% (up 0.46 percentage points) [5] Financial Summary - Revenue and profit forecasts for 2026-2028 are as follows: - 2026: Net profit of 465 million yuan, EPS of 2.23 yuan, P/E ratio of 27.0 times - 2027: Net profit of 559 million yuan, EPS of 2.67 yuan, P/E ratio of 22.4 times - 2028: Net profit of 682 million yuan, EPS of 3.27 yuan, P/E ratio of 18.4 times [5][8] - The company’s revenue is expected to grow from 3.387 billion yuan in 2025 to 5.354 billion yuan in 2028, reflecting a compound annual growth rate (CAGR) of approximately 15.5% [8] Business Strategy - The company has established a data-driven, multi-channel operational system, achieving online revenue of 2.197 billion yuan (up 10.37%) in 2025 [6] - The health monitoring segment grew by 20.08%, with strong performance from products like dual glucose and uric acid test strips [6] - The company has accelerated its overseas business, achieving revenue of 299 million yuan (up 405.05%) in 2025, supported by acquisitions and strategic partnerships [7]